Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant

Cancer Gene Therapy

Volumn 7, Issue 1, 2000, Pages 66-73

  Puhlmann, Markus ^a   Brown, Charles K ^a   Gnant, Michael ^a   Huang, James ^a   Libutti, Steven K ^a   Alexander, H Richard ^a   Bartlett, David L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biodistribution; Gene therapy; Luciferase; Thymidine kinase; Vaccinia

Indexed keywords

LUCIFERASE; PSORALEN; THYMIDINE KINASE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LIVER METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN CANCER; SUICIDE GENE; TISSUE DISTRIBUTION; TREATMENT OUTCOME; VACCINIA VIRUS; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALIA; MURINAE; MUS MUSCULUS; VACCINIA; VACCINIA VIRUS;

EID: 0033950819     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700075     Document Type: Article

References (18)

1. Kirn DH, McCormick F. Replicating viruses as selective cancer therapeutics. Mol Med Today. 1996;2:519-527.
2. Moss B. Vaccinia virus: a tool for research and vaccine development. Science. 1991;252:1662-1667.
3. Tartaglia J, Pincus S, Paoletti E. Poxvirus-based vectors as vaccine candidates. Crit Rev Immunol. 1990;10:13-30.
4. Peplinski GR, Tsung K, Casey MJ, et al. In vivo murine tumor gene delivery and expression by systemic recombinant vaccinia virus encoding interleukin-1β. Cancer J Sci Am. 1996;2:21-27.
5. Duller RML, Smith GL, Cremer K, et al. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature. 1985;317:813-815.
6. Davison AJ, Moss B. Structure of vaccinia virus early promoters. J Mol Biol. 1989;210:749-769.
7. Davison AJ, Moss B. Structure of vaccinia virus late promoters. J Mol Biol. 1989;210:771-784.
8. Earl PL, Moss B. Current protocols in molecular biology. In: Ausubel FM, Kinston R, Kingston RE, et al, eds. Current Protocols in Molecular Biology. New York: Greene/ Wiley Interscience;1991:16:15.1-16.18.10.
9. Tsung K, Yim JH, Marti W, Buller RM, Norton JA. Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light. J Virol. 1996; 70:165-171.
10. Davison AJ, Moss B. New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins. Nucleic Acids Res. 1990;18:4285-4286.
11. Andreansky SS, He B, Gillespie GY, et al. The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci USA. 1996;93:11313-11318.
12. Chung CS, Hsiao JC, Chang YS, et al. A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate. J Virol. 1998;72:1577-1585.
13. Brunner G, Reimbold K, Meissauer A, et al. Sulfated glycosaminoglycans enhance tumor cell invasion in vitro by stimulating plasminogen activation. Exp Cell Res. 1998;239: 301-310.
14. 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst. 1996;88:100-108.
15. Barinaga M. Viruses launch their own "star wars." Science. 1992;258:1730-1731.
16. Kotwal GJ, Moss B. Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature. 1988;335:176-178.
17. Whitman ED, Tsung K, Paxson J, et al. In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. Surgery. 1994;116:183-188.
18. Kianmanesh AR, Perrin H, Panis Y, et al. A "distant" bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. Hum Gene Ther. 1997;8:1807-1814.